Eradication of established tumors by CD8+ T cell adoptive immunotherapy - PubMed (original) (raw)
Eradication of established tumors by CD8+ T cell adoptive immunotherapy
H L Hanson et al. Immunity. 2000 Aug.
Free article
Abstract
We generated the DUC18 T cell receptor transgenic mouse expressing an H-2Kd -restricted transgenic T cell receptor specific for the syngeneic CMS5 fibrosarcoma rejection antigen mutated ERK2(136-144). DUC18 mice were capable of specifically eliminating lethal CMS5 tumor challenges, and transfer of DUC18 splenocytes to naive nontransgenic recipients conferred protection from subsequent and established CMS5 tumor burdens. Eradication of established tumor burdens by adoptive transfer of DUC18 splenocytes was dose and time dependent. Transferred tumor-specific T cells remained functional in vivo and capable of rejecting small tumors even in the presence of large, established tumor burdens. These findings highlight the kinetic battle between tumor growth and the production of a tumor-specific response and have critical implications for effective adoptive immunotherapy.
Similar articles
- CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
Hanson HL, Kang SS, Norian LA, Matsui K, O'Mara LA, Allen PM. Hanson HL, et al. J Immunol. 2004 Apr 1;172(7):4215-24. doi: 10.4049/jimmunol.172.7.4215. J Immunol. 2004. PMID: 15034034 - Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy.
Matsui K, O'Mara LA, Allen PM. Matsui K, et al. Int Immunol. 2003 Jul;15(7):797-805. doi: 10.1093/intimm/dxg078. Int Immunol. 2003. PMID: 12807818 - Stimulation through very late antigen-4 and -5 improves the multifunctionality and memory formation of CD8⁺ T cells.
Hosoi H, Ikeda H, Imai N, Amaike C, Wang L, Orito Y, Yamane M, Ueno H, Ideno M, Nukaya I, Enoki T, Mineno J, Takesako K, Hirano S, Shiku H. Hosoi H, et al. Eur J Immunol. 2014 Jun;44(6):1747-58. doi: 10.1002/eji.201343969. Epub 2014 May 11. Eur J Immunol. 2014. PMID: 24723437 - CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.
Tatum AM, Mylin LM, Bender SJ, Fischer MA, Vigliotti BA, Tevethia MJ, Tevethia SS, Schell TD. Tatum AM, et al. J Immunol. 2008 Sep 15;181(6):4406-17. doi: 10.4049/jimmunol.181.6.4406. J Immunol. 2008. PMID: 18768900 Free PMC article. - Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.
DiGiusto D, Cooper L. DiGiusto D, et al. Cytotherapy. 2007;9(7):613-29. doi: 10.1080/14653240701650320. Cytotherapy. 2007. PMID: 17943498 Free PMC article. Review.
Cited by
- Cancer therapy in mice using a pure population of CD8+ T cell specific to the AH1 tumor rejection antigen.
Stringhini M, Spadafora I, Catalano M, Mock J, Probst P, Spörri R, Neri D. Stringhini M, et al. Cancer Immunol Immunother. 2021 Nov;70(11):3183-3197. doi: 10.1007/s00262-021-02912-9. Epub 2021 Apr 1. Cancer Immunol Immunother. 2021. PMID: 33796916 Free PMC article. - Chemical augmentation of mitochondrial electron transport chains tunes T cell activation threshold in tumors.
Dotsu Y, Muraoka D, Ogo N, Sonoda Y, Yasui K, Yamaguchi H, Yagita H, Mukae H, Asai A, Ikeda H. Dotsu Y, et al. J Immunother Cancer. 2022 Feb;10(2):e003958. doi: 10.1136/jitc-2021-003958. J Immunother Cancer. 2022. PMID: 35115364 Free PMC article. - Cooperative action of CD8 T lymphocytes and natural killer cells controls tumour growth under conditions of restricted T-cell receptor diversity.
Shanker A, Buferne M, Schmitt-Verhulst AM. Shanker A, et al. Immunology. 2010 Jan;129(1):41-54. doi: 10.1111/j.1365-2567.2009.03150.x. Immunology. 2010. PMID: 20050329 Free PMC article. - Genetic instability as a driver for immune surveillance.
Aguadé-Gorgorió G, Solé R. Aguadé-Gorgorió G, et al. J Immunother Cancer. 2019 Dec 11;7(1):345. doi: 10.1186/s40425-019-0795-6. J Immunother Cancer. 2019. PMID: 31829285 Free PMC article. - Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP. Overwijk WW, et al. J Exp Med. 2003 Aug 18;198(4):569-80. doi: 10.1084/jem.20030590. J Exp Med. 2003. PMID: 12925674 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous